Similarly, we observed more functional mutations in TP53 in HER2+/ER− tumours (67.5%) than in HER2+/ER+ tumours (42.6%), and more functional mutations in GATA3 in the HER2+/ER+ cohort (8.2%; HER2+/ER−=0.5%) (Supplementary Fig. 7). The gene discussed is TP53; the disease is neoplasm.